Thoughts on PE 22-28 and TREK-1 blockade?
Posted by optimizer_jenna in Research & News - 31 points, 4 comments.
I was reading about /peptides/pe-22-28 and the way it blocks the TREK-1 potassium channel. The idea that it can increase synaptogenesis and neurogenesis faster than SSRIs sounds very promising, tbh. As someone who is quite skeptical of long term medication, a fast acting option for mood and neuroplasticity is interesting.
Actually, it seems a bit TOO good to be true since it is still preclinical. I worry that we are jumping the gun when there is no established human safety data yet. I have tried some other nootropics and often the real world results are much smaller than the animal models suggest. It could just be hype.
Since I am still new to this, I am wondering if anyone here has actually seen any human reports or anecdotal data on this one? I cannot find much beyond the basic research descriptions. Do you think the rapid effect on serotonin signaling is actually sustainable, or would the brain just compensate after a while? I would love to see some actual citations if anyone has found some. Thank you for any help.
Comments
- fasted_scientist: I reckon you are spot on to be skeptical here. Ngl, the jump from rodent models to humans is where most of these hype cycles die. I have not seen any reliable human reports on PE 22-28, and that is usually a red flag when people start talking about it as an SSRI replacement. The brain is brilliant at finding a balance, so I would bet on some kind of compensation happening if you blocked those channels long term. It seems a bit too tidy. Unless someone can post a actual human trial or a decent s
- optimizer_jenna: I actually agree with you about the compensation risk. If the brain finds a way to bypass that channel blockade, the effect might just disappear. Tbh, I am finding it hard to find anything regarding long term use. Most papers I see just stop after the acute phase in mice. Do you think there is a way to see if compensatory mechanisms are likely just by looking at the channel's expression levels in other studies?
- grant95: Fair point. The rodent-to-human gap is where most of these compounds quietly fade, and i haven't seen a single human trial with PE 22-28 outside of early-phase stuff. I've run a few personal nootropic experiments and the real-world results tend to be way smaller than the animal data suggests. The brain's compensation angle is solid too, block a channel long enough and the system usually rebalances itself somewhere you don't expect. Have you come across any human safety data, or is it still pure
- optimizer_jenna: I actually agree with your point about the brain rebalancing itself. That compensation angle is quite scary to think about for long term use. Tbh I have not found any human safety data yet, it seems to be purely preclinical for now. That is exactly why I am being so cautious. Since you have run personal nootropic experiments, did you notice any sudden crashes when you stopped using things?
Community discussion - research and educational context only. Not medical advice.